Exagen inc. collaboration leads to characterization of broad autoreactivity in severe covid-19 patients

San diego, sept. 01, 2022 (globe newswire) -- exagen inc. (nasdaq: xgn), a leading provider of autoimmune testing solutions, announced today that its collaboration with dr. iÑaki sanz at emory university has led to a publication in nature, found here. exagen's clinical test offerings, run on samples from severe covid-19 patients, helped researchers from emory characterize the autoimmune profiles induced by sars-cov-2 infection.
XGN Ratings Summary
XGN Quant Ranking